Abeona Therapeutics Inc ABEO.OQ ABEO.O is expected to show a rise in quarterly revenue when it reports results on March 17 (estimated) for the period ending December 31 2024
The Cleveland Ohio-based company is expected to report revenue of $100 thousand, according to the mean estimate from 5 analysts, based on LSEG data.
LSEG's mean analyst estimate for Abeona Therapeutics Inc is for a loss of 35 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Abeona Therapeutics Inc is $15.50, above its last closing price of $5.28.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Sep. 30 2024 | -0.41 | -0.40 | -0.63 | Missed | -55.9 |
Jun. 30 2024 | -0.39 | -0.36 | 0.19 | Beat | 152.2 |
Mar. 31 2024 | -0.51 | -0.51 | -1.16 | Missed | -126 |
Dec. 31 2023 | -0.47 | -0.77 | Missed | -63.8 | |
Sep. 30 2023 | -0.53 | -0.53 | -0.48 | Beat | 8.9 |
Jun. 30 2023 | -0.71 | -0.68 | -0.92 | Missed | -35.3 |
Mar. 31 2023 | -0.62 | -0.58 | -0.54 | Beat | 6.9 |
Dec. 31 2022 | -0.75 | 1.53 | Beat | 304 |
This summary was machine generated March 14 at 13:08 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。